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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016PILR deﬁcient neutrophils showed enhanced adhesion and
spreading on IC compared to WT. IC adhesion-dependent H2O2
production of neutrophils was also increased in PILR -/- mice
compared to WT animals.
Conclusions: PILR deﬁciency resulted in deteriorated renal damage
in murine antibody-mediated glomerulonephritis compare to WT
mice. The present study indicated that PILR negatively regulates
antibody-mediated leukocyte recruitment by inhibition of m 2
integrin activation.
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Introduction: The immune system controls the gut microbiota.
Transplant recipients are treated with immunosuppressive (IS)
therapies which could impact host-microbial interactions. We
examined the impact of IS drugs on gut microbiota and on the
secretion of ileal antimicrobial peptides.
Methods: Mice were treated for 14 days with prednisolone,
mycophenolate mofetil, tacrolimus, a combination of these 3 drugs,
everolimus or water. Faeces were collected before and after treat-
ment initiation. Ileal samples were collected after sacriﬁce. Faecal
and ileal microbiota was analyzed by pyrosequencing of 16S rRNA
genes, and C-type lectins were assessed in ileal tissues by RT-qPCR.
Results: Prednisolone decreased Bacteroidetes and increased Fir-
micutes in the faeces. While prednisolone disrupted faecal micro-
bial community structure, no single OTU was consistently affected
in experimental replicates. In ileal samples, the genus Clostridia
sensu stricto was dramatically reduced in the prednisolone and
combined IS drug groups. These modiﬁcations corresponded to an
altered expression of C-type lectins, Reg3 and Reg3. Interestingly,
the combined IS treatment enabled a commensal Escherichia coli to
ﬂourish, and dramatically increased colonization by uropathogenic
E. coli strain 536.
Conclusions: IS treatment alters innate antimicrobial defenses and
disrupts the gut microbiota which leads to overgrowth of indige-
nous E. coli and facilitates colonization by opportunistic pathogens.
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Introduction: Induction therapy of proliferative lupus nephritis
still requires the use of unselective immunosuppressive drugs with
signiﬁcant toxicities. More speciﬁc drugs with equal efﬁcacy but
fewer side effects are needed. In search of suitable molecular targets
we considered monocyte chemoattractant protein (MCP-1/CCL2)
and stromal cell-derived factor (SDF-1/CXCL12), which both
contribute to the onset and progression of proliferative lupus
nephritis yet through different mechanisms. We hypothesized that
dual antagonism of the homeostatic chemokine CXCL12 and the pro-
inﬂammatory chemokine CCL2 could be as potent on lupus
nephritis as the unselective and toxic immunosuppressant cyclo-
phosphamide (CYC).
Methods: We used l-enantiomeric RNA Spiegelmer chemokine
antagonists, i.e. the CCL2-speciﬁc mNOX-E36 and the CXCL12-
speciﬁc NOX-A12. Female MRLlpr/lpr mice were treated (subcu-
taneous injection) from week 12 to 24 of age of age either with
single regimen of anti-CXCL12 (13.4mg/kg) or anti-CCL2 (14.4 mg/
kg) or both along with standard regimen with cyclophosphamide
(CYC) (30mg/kg).
Tissues were harvested for histopathological evaluation at the
end of the treatment period. Blood and urine samples were obtained
at monthly intervals for the estimations of urinary albumin (ELISA:
Bethyl Labs, Montgomery, TX, USA) as well as serum and urinary
creatinine (Jaffé reaction: DiaSys Diagnostic Systems, Holzheim,
Germany). Inﬂammatory gene proﬁle was determined by RTPCR.
All experiments were performed according to German animal pro-
tection laws and had been approved by the local government
authorities.
Results: Dual blockade was signiﬁcantly more effective than
monotherapy in preventing proteinuria and BUN. Dual blockade
was also more effective in controlling the histopathological indices
of disease activity and chronicity. Dual blockade reduced IgG im-
munoglobulins, CD3+ lymphocytes and macrophages more efﬁ-
ciently than monotherapy. Dual blockade also reduced renal IL-6,
IL-12p40, CCL5, CCL-2 and CCR2 mRNA expression. Effects of dual
blockade on kidney functional parameters are at par with CYC
standard regimen.
Conclusions: Dual blockade of CCL2 and CXCL12 can be as potent
as CYC to suppress the progression of proliferative lupus nephritis
in female MRLlpr/lpr mice probably because the respective che-
mokine targets mediate different disease pathomechanisms, i.e.
systemic autoimmunity and peripheral tissue inﬂammation.
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Introduction: Lymphocytes occupy pivotal roles in immune-medi-
ated kidney diseases. However the respective contributions of
different lymphocyte subsets in diseased human kidneys are not
certain, with previous studies limited by the methodology of
immunohistochemistry to identify inﬁltrating cells.Kidney International Reports (2016) 1, S1–S22
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016Methods: We developed novel protocols for extracting renal lym-
phocytes from healthy kidney tissue and diseased biopsies with and
without ﬁbrosis. Lymphocyte subsets were identiﬁed, enumerated
and phenotyped by twelve-colour ﬂow cytometry.
Results: We detected signiﬁcantly elevated numbers of T cells
(CD45+CD3+) in diseased biopsies with interstitial ﬁbrosis
compared with healthy kidney tissue. Within this T cell compart-
ment, numbers of T helper cells (CD3+CD4+) and cytotoxic T cells
(CD3+CD8+) were elevated in ﬁbrotic kidney tissue. Moreover,
numbers of / T cells (CD3+ / +) and natural killer (NK)-T cells
(CD3+CD16+) were signiﬁcantly increased in ﬁbrotic biopsies
compared with diseased biopsies without ﬁbrosis and healthy
kidney tissue. Of CD3- lymphoid cells, NK cells (CD3-CD56+) were
elevated in ﬁbrotic kidney tissue, in particular CD56brightCD16-/+
NK cells, the major cytokine-producing NK subtype in human
peripheral tissues and secondary lymphoid organs. B cells (CD3-
CD19+) were also increased in ﬁbrotic kidney tissue. Additionally,
numbers of / T cells, NK-T, NK and B cells correlated with loss of
kidney function (based on eGFR levels). Expression of activation
molecule CD69 on renal lymphocytes was increased in ﬁbrotic bi-
opsies compared with healthy kidney tissue, indicative of a path-
ogenic phenotype.
Conclusions: Collectively, our data show that lymphocyte
subsets are differentially recruited into diseased human kid-
neys. The representation of speciﬁc lymphocyte subsets also
correlates with the clinical severity of chronic kidney disease.
Further identiﬁcation and functional dissection of these
lymphocyte subsets will enable the development of targeted
treatment strategies.
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Introduction: The lysosomal cysteine protease cathepsin (Cat)-S
processes the invariant chain-MHC II complex inside antigen-
presenting cells as a central pathomechanism of autoimmune dis-
eases. In addition, activated myeloid cells release Cat-S and was
recently described to activate protease-activated receptor (PAR)-2
in extracellular compartments (Kumar S, et al JASN 2015). We
hypothesized that in lupus nephritis Cat-S blockade can target both
pathomechanisms and can elicit synergistic therapeutic effects
disease outcomes.
Methods: Female MRL-Fas(lpr) mice with spontaneous autoimmune
tissue injury were treated with different doses of the oral Cat-S
antagonist RO5459072 or mycophenolate mofetil (MMF) or vehicle
from week 11 or 15 to 19 of age. To evaluate the Cat-S induced
micro-vascular damage, female MRL-Fas(lpr) mice were injected
with recombinant Cat-S with or without concomintant Cat-S or
PAR2 blockade and urine albumin levels were measured at different
time intervals. In-vitro studies with PAR2 expressing endothelial
cells were used to conﬁrm the Cat-S induced endothelial activation
and dysfunction.Kidney International Reports (2016) 1, S1–S22Results: Cat-S blockade dose-dependently protected aberrant sys-
temic autoimmunity, by reducing the plasma cytokine levels,
activation myeloid cells and lymphocytes, and hyper-
gammaglobulinemia. Especially IgG auto-antibodies were sup-
pressed. Of note while (MHC-II-independent) IgM antibodies were
not affected by Cat-S blockade but strongly suppressed by MMF.
Cat-S blockade dose-dependently suppressed immune complex
glomerulonephritis together with a profound and early effect on
proteinuria, which was not shared by MMF. In fact, intravenous
Cat-S injection induced severe glomerular endothelial cell injury
and albuminuria, which was entirely prevented by Cat-S or PAR2
blockade. In-vitro studies conﬁrm that Cat-S induces endothelial
cell activation and injury via PAR-2. PAR2 silencing in endothelial
cells using siRNA signiﬁcantly protected the endothelial injury in-
vitro.
Conclusions: Therapeutic Cat-S blockade suppresses synergistic
systemic and peripheral pathomechanisms of autoimmune tissue
injury, hence, Cat-S is a promising therapeutic in autoimmune
diseases.
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Introduction: Diabetic Nephropathy (DN) remains an unmet medi-
cal challenge as its prevalence is projected to continue to increase
and speciﬁc medicines for treatment remain undeveloped. Activa-
tion of the immune system, in particular T-cells, is emerging as a
possible mechanism underlying DN disease progression in humans
and animal models. We hypothesized that inhibition of T-cell
activation will ameliorate DN. Interaction of B7-1 (CD80) on the
surface of antigen presenting cells with its binding partners,
CTLA4 (CD152) and CD28 on T-cells, is essential for T-cell activa-
tion. In this study we used a soluble CTLA4-Fc fusion protein to
block cell surface B7-1, preventing the cellular interaction and
inhibiting T-cell activation.
Methods: The CTLA4-Fc Abatacept was dosed i.p. in the Strepto-
zotocin-induced Diabetic Nephropathy mouse model in both pre-
vention and intervention modes. Renal damage was assessed by
albuminuria and renal B7.1 positive cells and lymphocytes were
measured by immunohistochemistry. Gene expression interrogated
by real-time PCR and protein expression by Western blotting.
Differentiated human immortalized podocytes were used for in
vitro studies.
Results: When CTLA4-Fc was dosed in an animal model of DN, it
reduced albuminuria in both prevention and intervention modes.
The number of T-cells inﬁltrating the kidneys of DN animals
correlated with the degree of albuminuria and treatment with
CTLA4-Fc reduced the number of renal T-cells. As B7-1 induction
has been recently proposed to underlie podocyte damage in DN,
CLTA4-Fc could be efﬁcacious in DN by protecting podocytes.
However, this does not appear to be the case as B7-1 was not
expressed in: 1) kidneys of DN animals; 2) stimulated human
podocytes in culture; or 3) glomeruli of DN patients.
Conclusions: We conclude that CTLA4-Fc ameliorates DN by
blocking T-cell activation and not by protecting podocytes.S17
